Structural modifications modulate stability of glutathione-activated arylated diazeniumdiolate prodrugs

JS-K, a diazeniumdiolate-based nitric oxide (NO)-releasing prodrug, is currently in late pre-clinical development as an anti-cancer drug candidate. This prodrug was designed to be activated by glutathione (GSH) to release NO. To increase the potency of JS-K, we are investigating the effect of slowin...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Nandurdikar, Rahul S., Maciag, Anna E., Holland, Ryan J., Cao, Zhao, Shami, Paul J., Anderson, Lucy M., Keefer, Larry K., Saavedra, Joseph E.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2012
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3590845/
https://ncbi.nlm.nih.gov/pubmed/22480849
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bmc.2012.02.045
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares